
MoonLake secures $500m for lead drug, plus other financings
MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, bolstering its cash reserves as it ushers its lead drug for inflammatory diseases through late-stage development. The four-year-old Swiss biotech …